Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip North

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Inquiry : a Journal of Medical Care Organization, Provision and Financing|September 9, 2011
Geographic market definition: the case of Medicare-reimbursed skilled nursing facility careJohn R Bowblis, Phillip North
Cell Reports|January 29, 2013
RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interactionAdam C Wilkinson, Erica Ballabio, Huimin Geng, et al.
Cell Reports|December 30, 2015
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Juliana M Benito, Laura Godfrey, Kensuke Kojima, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Inquiry : a Journal of Medical Care Organization, Provision and Financing|September 9, 2011
Geographic market definition: the case of Medicare-reimbursed skilled nursing facility careJohn R Bowblis, Phillip North
Cell Reports|January 29, 2013
RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interactionAdam C Wilkinson, Erica Ballabio, Huimin Geng, et al.
Cell Reports|December 30, 2015
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Juliana M Benito, Laura Godfrey, Kensuke Kojima, et al.
Pageof 1